Cidel Asset Management Inc. Buys 34 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cidel Asset Management Inc. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 331 shares of the biopharmaceutical company’s stock after acquiring an additional 34 shares during the period. Cidel Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $236,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at about $37,000. Private Wealth Management Group LLC boosted its position in Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 39 shares during the period. Finally, Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $39,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $710.00 on Friday. The company’s fifty day moving average price is $715.81 and its 200-day moving average price is $911.09. The stock has a market cap of $78.02 billion, a PE ratio of 18.55, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the firm posted $11.86 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Oppenheimer decreased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. Finally, Robert W. Baird lowered their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.